Evidence map›Paper›PMID 24237936›Full record

ArticleRetrovirology2013

Dual-acting stapled peptides target both HIV-1 entry and assembly.

Hongtao Zhang, Francesca Curreli, Abdul A Waheed, Peter Y Mercredi, Mansi Mehta, Pallavi Bhargava, Daniel Scacalossi, Xiaohe Tong, Shawn Lee, Alan Cooper and 3 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. HIV Capsid Inhibitors Beyond PF74.Diseases (Basel, Switzerland) · 2019
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Hongtao Zhang
Francesca Curreli
Abdul A Waheed
Peter Y Mercredi
Mansi Mehta
Pallavi Bhargava
Daniel Scacalossi
Xiaohe Tong
Shawn Lee
Alan Cooper
Michael F Summers
Eric O Freed
Asim K DebnathLaboratory of Molecular Modeling, Drug Design, Lindsley F, Kimball Research Institute of the New York Blood Center, 310 E 67th Street, New York, NY 10065, USA. adebnath@nybloodcenter.org.
New York Blood Center · USUniversity of Maryland, Baltimore County · USHoward Hughes Medical Institute · USNational Cancer Institute · USNational Institutes of Health · USUniversity of Glasgow · GB

Funding

EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Inhibition of HIV-1 MaturationZIABC010778 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FREED, ERIC · 2009 to 2025
$9.7M
Rational Design of antivrials targeted to HIV-1 capsidR01AI081604 · NIAID · NEW YORK BLOOD CENTER · PI DEBNATH, ASIM K · 2009 to 2013
$2.9M
NMR STUDIES OF HIV-1 PROTEINSR01AI030917 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SUMMERS, MICHAEL F. · 1991 to 1996
–
Biotechnology and Biological Sciences Research Council B20089Intramural NIH HHSNIAID NIH HHS R01 AI081604NIAID NIH HHS R01 AI30917NIGMS NIH HHS R25 GM055036NIGMS NIH HHS R25 MBRS-IMSD GM55036
6 · The paper itself

Abstract

backgroundPreviously, we reported the conversion of the 12-mer linear and cell-impermeable peptide CAI to a cell-penetrating peptide NYAD-1 by using an i,i + 4 hydrocarbon stapling technique and confirmed its binding to the C-terminal domain (CTD) of the HIV-1 capsid (CA) protein with an improved affinity (K(d) ~ 1 μM) compared to CAI (K(d) ~ 15 μM). NYAD-1 disrupts the formation of both immature- and mature-like virus particles in in vitro and cell-based assembly assays. In addition, it displays potent anti-HIV-1 activity in cell culture against a range of laboratory-adapted and primary HIV-1 isolates.

resultsIn this report, we expanded the study to i,i + 7 hydrocarbon-stapled peptides to delineate their mechanism of action and antiviral activity. We identified three potent inhibitors, NYAD-36, -66 and -67, which showed strong binding to CA in NMR and isothermal titration calorimetry (ITC) studies and disrupted the formation of mature-like particles. They showed typical α-helical structures and penetrated cells; however, the cell penetration was not as efficient as observed with the i,i + 4 peptides. Unlike NYAD-1, the i,i + 7 peptides did not have any effect on virus release; however, they impaired Gag precursor processing. HIV-1 particles produced in the presence of these peptides displayed impaired infectivity. Consistent with an effect on virus entry, selection for viral resistance led to the emergence of two mutations in the gp120 subunit of the viral envelope (Env) glycoprotein, V120Q and A327P, located in the conserved region 1 (C1) and the base of the V3 loop, respectively.

conclusionThe i,i + 7 stapled peptides derived from CAI unexpectedly target both CA and the V3 loop of gp120. This dual-targeted activity is dependent on their ability to penetrate cells as well as their net charge. This mechanistic revelation will be useful in further modifying these peptides as potent anti-HIV-1 agents.

Indexed as

Anti-HIV AgentsCell LineHIV-1HIV Core Protein p24HIV Envelope Protein gp120HumansPeptidesProtein BindingVirus AssemblyVirus InternalizationAnti-HIV Agentsgp120 protein, Human immunodeficiency virus 1HIV Core Protein p24HIV Envelope Protein gp120Peptides

Identifiers

PMID24237936
PMCPMC3842668
OpenAlexW2126953236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.